Lilly Pharmaceutical’s Mounjaro (tirzepatide) is a once-weekly injection that promotes weight loss by mimicking the effects of incretins. This combination of a GLP-1 and a glucose-dependent insulinotropic polypeptide (GIP) yields weigh loss results comparable to surgical options.